The Asian oncology market: tough challenges but promising prospects
This article was originally published in SRA
Executive Summary
The market for oncology products is stronger in Asia than in more developed parts of the world, but companies still face many challenges getting their cancer therapies to market. With a focus on Taiwan, South Korea and China, Questa Lin reports on the key areas of stakeholder influence, the pricing and reimbursement environment and possible changes in the field of health technology assessment.